Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?
Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...
Hosted on MSN13d
Where Will Vertex Pharmaceuticals Be in 10 Years?
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...
StockStory.org on MSN5d
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
American Association of Individual Investors3d
Which Is a Better Investment, Elastic N.V. or Vertex, Inc. Stock?
Learn more about whether Elastic N.V. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...
Vertex price target raised to $60 from $57 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...
Pacific Coast Business Times1h
Latigo raises $150M to advance pipeline through clinical trials
If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...
BioPharma Dive18d
Vertex’s new pain drug gets first coverage nod from major insurer
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
American Association of Individual Investors3d
Which Is a Better Investment, Open Text Corporation or Vertex, Inc. Stock?
Learn more about whether Open Text Corporation or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...
Chalkbeat on MSN10d
Linda McMahon’s first official K-12 visit: A Bronx charter school
U.S. Education Secretary Linda McMahon took a tour of Vertex Partnership Academies founded by Ian Rowe, a senior fellow at ...
Goldman Sachs Analyst Anticipates Clarity On Vertex's Investment Roadmap And Product Monetization At Investor Day
Goldman Sachs analyst Adam Hotchkiss expressed expectations on Vertex, Inc. (NASDAQ:VERX) ahead of its first Investor Day as ...
Vertex Pharmaceuticals exec Altshuler sells 3,231 common shares
In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the ...